Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Korro Bio ( (KRRO) ).
On May 19, 2026, Korro Bio announced it has selected KRRO-111, a GalNAc-conjugated oligonucleotide delivered subcutaneously to liver cells, as a development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency, adding the program to its pipeline alongside KRRO-121 for hyperammonemia in urea cycle disorders. Preclinical data in PiZZ mouse models showed more than 90% editing of the SERPINA1 transcript, approximately 90% restoration of functional M-AAT protein, near-elimination of pathogenic Z-protein production, and progressive clearance of protein aggregates, underscoring a potentially best-in-class profile and reinforcing Korro’s strategic positioning in RNA-based genetic medicines.
The most recent analyst rating on (KRRO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
The score is held down primarily by weak financial performance—declining/volatile revenue, large ongoing losses, and substantial cash burn—despite a currently manageable leverage profile. A meaningful positive offset is the oversubscribed $85M PIPE, which extends the funding runway and improves liquidity visibility. Technicals remain soft with the stock below key short-term moving averages, and valuation is not supported by earnings (negative P/E).
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Korro Bio, Inc. is a Cambridge, Mass.-based biopharmaceutical company developing genetic medicines using its OPERA RNA editing platform to treat rare and highly prevalent diseases. The platform uses precise, tissue-directed oligonucleotides, including GalNAc-conjugated modalities for subcutaneous delivery, to edit native mRNA transcripts and generate therapeutic proteins without altering DNA.
Average Trading Volume: 174,647
Technical Sentiment Signal: Sell
Current Market Cap: $146.8M
For an in-depth examination of KRRO stock, go to TipRanks’ Overview page.